Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC
NCT ID: NCT04153097
Last Updated: 2023-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2020-07-30
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
NCT05055908
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
NCT03195491
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
NCT03769129
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
NCT04825873
Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type
NCT05023837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multi-center non-interventional study, advanced NSCLC patients who treated with pembrolizumab and provide written informed consent will be included. The main objective of this study is to evaluate pembrolizumab efficacy and safety in the clinical practice and explore the prognosis-relevant factors of advanced NSCLC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pembrolizumab-treated advanced NSCLC
Patients with advanced non-small cell lung cancer treated with pembrolizumab
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who receive pembrolizumab for advanced NSCLC.
3. Patients who provided written informed consent.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jianying Jianying, MD
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital of Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of College of Medicine Zhejiang University
Hangzhou, Zhejiang, China
Second Affiliated Hospital, Zhejiang University of Medicine
Hangzhou, Zhejiang, China
the First Hospital of Jiaxing
Jiaxing, Zhejiang, China
Jinhua Guangfu Hospital
Jinhua, Zhejiang, China
Ningbo Medical Center Lihuili Eastern Hospital
Ningbo, Zhejiang, China
Quzhou People's Hospital
Quzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
The People's Hospital of Zhuji
Zhuji, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yaodong Tang, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZYHX-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.